Neil Woodford's top ten holdings in his Woodford Equity Income fund contain few surprises, with AstraZeneca, GlaxoSmithKline and British American Tobacco the three largest positions.
Revealed this morning, the top ten positions in the newly-launched fund account for 50% of his total portfolio, and are dominated by the defensive sectors which the manager has historically favoured...
To continue reading this article...
Join Investment week
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
